论文部分内容阅读
目的探讨重组人白介素-11(rh IL-11)在急性白血病化疗后血小板减少症的临床治疗效果。方法选取平煤神马医疗集团总医院2010年2月—2014年6月确诊为急性白血病化疗后血小板减少症的患者共46例,随机分为治疗组和对照组,各23例。两组患者均为首次接受化疗,治疗组在化疗结束后48h皮下注射rh IL-11,直至血小板升至100×109/L,连续用药时间不超过14d;对照组不给予rh IL-11治疗,待血小板低于10×109/L或有出血倾向时输注血小板悬液。观察两组的临床治疗效果、化疗后血小板最低值、血小板水平恢复时间与人均血小板输注量及皮下注射重组人白介素-11的不良反应发生率。结果治疗组总有效率(91.3%)显著高于对照组(73.9%)(P<0.05);两组间血小板最低值无明显差异(P>0.05);治疗组血小板水平恢复时间较对照组明显缩短(P<0.05);治疗组人均血小板输注量明显低于对照组(P<0.05);治疗组不良反应程度轻微,停药后均能消退。结论重组人白介素-11对急性白血病化疗后血小板减少的疗效显著,明显缩短病程,且不良反应少,具有较好的临床应用价值,值得推广。
Objective To investigate the clinical effect of recombinant human interleukin-11 (IL-11) on thrombocytopenia after acute leukemia chemotherapy. Methods Forty-six patients with thrombocytopenia diagnosed as acute leukemia after chemotherapy in Pingmu Shenma Medical Group General Hospital from February 2010 to June 2014 were randomly divided into treatment group and control group, with 23 cases in each group. The patients in the two groups received chemotherapy for the first time. The patients in the treatment group were given rhIL-11 subcutaneously 48h after the chemotherapy, until the platelets increased to 100 × 109 / L and the continuous treatment time did not exceed 14 days. The control group was not given rh IL-11, When platelets below 10 × 109 / L or a tendency to bleeding platelet transfusion. To observe the clinical treatment effect of two groups, the lowest value of platelet after chemotherapy, platelet recovery time and per capita platelet transfusion and subcutaneous injection of recombinant human interleukin-11 adverse reactions. Results The total effective rate (91.3%) in the treatment group was significantly higher than that in the control group (73.9%) (P <0.05). There was no significant difference between the two groups (P> 0.05). The recovery time of platelet in the treatment group was significantly longer than that in the control group (P <0.05). The mean platelet transfusion volume in the treatment group was significantly lower than that in the control group (P <0.05). The adverse reactions in the treatment group were mild and could be dissipated after stopping the treatment. Conclusion Recombinant human interleukin-11 has a significant therapeutic effect on thrombocytopenia after chemotherapy in patients with acute leukemia, significantly shortened the course of the disease, and has fewer adverse reactions, which has a good clinical value and is worthy of promotion.